Englander Institute for Precision Medicine

Publications

Found 851 results
Author Title Type [ Year(Asc)]
2024
Kasi PM, Lee JK, Pasquina LW, Decker B, Borre PVanden, Pavlick DC, Allen JM, Parachoniak C, Quintanilha JCF, Graf RP et al..  2024.  Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.. Clin Cancer Res. 30(4):836-848.
Meleshko D, Prjbelski AD, Raiko M, Tomescu AI, Tilgner H, Hajirasouliha I.  2024.  cloudrnaSPAdes: isoform assembly using bulk barcoded RNA sequencing data.. Bioinformatics. 40(2)
Li S, Wong A, Sun H, Bhatia V, Javier G, Jana S, Wu Q, Montgomery RB, Wright JL, Lam H-M et al..  2024.  A combinatorial genetic strategy for exploring complex genotype-phenotype associations in cancer.. Nat Genet. 56(3):371-376.
Batra R, Krumsiek J, Wang X, Allen M, Blach C, Kastenmüller G, Arnold M, Ertekin-Taner N, Kaddurah-Daouk R.  2024.  Comparative brain metabolomics reveals shared and distinct metabolic alterations in Alzheimer's disease and progressive supranuclear palsy.. Alzheimers Dement.
Al-Ishaq RKhalid, Ferrara CR, Stephan N, Krumsiek J, Suhre K, Montrose DC.  2024.  A Comprehensive Metabolomic and Microbial Analysis Following Dietary Amino Acid Reduction in Mice.. Metabolites. 14(12)
Izadmehr S, Fernandez-Hernandez H, Wiredja D, Kirschenbaum A, Lee-Poturalski C, Tavassoli P, Yao S, Schlatzer D, Hoon D, Difeo A et al..  2024.  Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis.. bioRxiv.
Siew K, Nestler KA, Nelson C, D'Ambrosio V, Zhong C, Li Z, Grillo A, Wan ER, Patel V, Overbey E et al..  2024.  Cosmic kidney disease: an integrated pan-omic, physiological and morphological study into spaceflight-induced renal dysfunction.. Nat Commun. 15(1):4923.
Lira MCecilia, Galluzzi L, Vanpouille-Box C.  2024.  COX2-dependent suppression of anticancer immunity.. Trends Cancer.
Noch EK, Palma L, Yim I, Bullen N, Barnett D, Walsh A, Bhinder B, Benedetti E, Krumsiek J, Gurvitch J et al..  2024.  Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production.. Proc Natl Acad Sci U S A. 121(8):e2317343121.
Beltrán-Visiedo M, Del Valle ASerrano-, Jiménez-Aldúan N, Soler-Agesta R, Naval J, Galluzzi L, Marzo I.  2024.  Cytofluorometric assessment of calreticulin exposure on CD38+ plasma cells from the human bone marrow.. Methods Cell Biol. 189:189-206.
Uemura M, Kikukawa H, Hashimoto Y, Uemura H, Mizokami A, Kato M, Matsushima H, Kosaka T, Nakamura M, Fukasawa S et al..  2024.  Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.. Cancer Med. 13(21):e70029.
Markowitz GJ, Ban Y, Tavarez DA, Yoffe L, Podaza E, He Y, Martin MT, Crowley MJP, Sandoval TA, Gao D et al..  2024.  Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve immunotherapy.. Nat Immunol. 25(10):1884-1899.
Ohara K, Assaad MAl, McNulty SN, Alnajar H, Sboner A, Wilkes DC, He F, Xiang JZhaoying, Mathew S, Elemento O et al..  2024.  Detection of rare and novel gene fusions in patients with diffuse glioma: An institutional retrospective study.. J Neuropathol Exp Neurol.
Klomp JE, J Diehl N, Klomp JA, A Edwards C, Yang R, Morales AJ, Taylor KE, Drizyte-Miller K, Bryant KL, Schaefer A et al..  2024.  Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.. Science. 384(6700):eadk0850.
Greenberg JA, Shah Y, Ivanov NA, Marshall T, Kulm S, Williams J, Tran C, Scognamiglio T, Heymann JJ, Lee-Saxton YJoo et al..  2024.  Developing a predictive model for metastatic potential in pancreatic neuroendocrine tumor.. J Clin Endocrinol Metab.
Forbes ANeil, Xu D, Cohen S, Pancholi P, Khurana E.  2024.  Discovery of therapeutic targets in cancer using chromatin accessibility and transcriptomic data.. Cell Syst.
McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K, Jang GHo, Walch H, Aveson VG, Falvo DJ et al..  2024.  Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.. Cancer Cell. 42(9):1614-1629.e5.
Risnik D, Colado A, Podaza E.  2024.  Editorial: Myeloid cell reprogramming: molecular pathways involved in disease development.. Front Immunol. 15:1414482.
Shore ND, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Tombal B, Nordquist L, Cookson M, Verholen F et al..  2024.  Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.. Oncologist. 29(3):235-243.
Windon A, Assaad MAl, Hadi K, Mendelson N, Hissong E, Deshpande A, Tranquille M, Mclee J, Levine MF, Patel M et al..  2024.  Emerging molecular phenotypes and potential therapeutic targets in esophageal and gastric adenocarcinoma unearthed by whole genome and transcriptome analyses.. Pathol Res Pract. 266:155788.
Assaad MAl, Hadi K, Tu J, Levine MF, Patel M, Deshpande A, Manohar J, Sigouros M, Sboner A, Chapman-Davis E et al..  2024.  Enhancing the detection of clinically relevant biomarkers in advanced uterine and tubo-ovarian carcinomas through genome-wide analysis.. Pathol Res Pract. 266:155773.
Cicin I, Plimack ER, Gurney H, Leibowitz R, Alekseev BY, Parnis FX, Peer A, Necchi A, Bellmunt J, Nishiyama H et al..  2024.  Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.. BMC Cancer. 23(Suppl 1):1256.
Mack TM, Raddatz MA, Pershad Y, Nachun DC, Taylor KD, Guo X, Shuldiner AR, O'Connell JR, Kenny EE, Loos RJF et al..  2024.  Epigenetic and proteomic signatures associate with clonal hematopoiesis expansion rate.. Nat Aging.
Galassi C, Esteller M, Vitale I, Galluzzi L.  2024.  Epigenetic control of immunoevasion in cancer stem cells.. Trends Cancer.
Spada S, Galluzzi L.  2024.  Epigenetic regulation of cancer.. Int Rev Cell Mol Biol. 387:xiii-xvii.